Duality Advisers, LP Tricida, Inc. Transaction History

Duality Advisers, LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 13, 2021	SELL	$4.52 - $7.8 $556,633 - $960,562	-123,149 Closed	0 $0
Q4 2020 Feb 09, 2021	SELL	$4.37 - $9.46 $31,337 - $67,837	-7,171 Reduced 5.5%	123,149 $868,000
Q3 2020 Nov 12, 2020	BUY	$8.56 - $26.93 $1.12 Million - $3.51 Million	130,320 New	130,320 $1.18 Million

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Duality Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Duality Advisers, LP with notifications on news.